While many of us are considering what our grilling or lake plans might be for the upcoming weekend, a major pharmaceutical company is getting ready to flood the market with flu vaccines.
Sanofi Pasteur plans to celebrate their 120th anniversary by inundating the market with flu vaccines. The 70 million doses for the 2017-2018 flu season has been blessed by the FDA. The specific type of vaccine is called Fluzone high-dose vaccine. It claims a 60 percent success rate in the elderly (which means it fails 40 percent of the time). Other doses include Fluzone Intradermal Quadrivalent and Quadrivalent.
The vaccines should arrive in pharmacies and doctor offices by August, just before the school year starts so that major flu shot campaigns can be thrust into effect.
Via Pocono Record
“It reminds us of our innovation and growth as we came to understand the science of influenza and its impact on human health,” Associate Vice President and Regional Medical Head, North America, David Greenberg, M.D., said.
Subscribe now and receive 3 Free Dr. Tenpenny eBooks!
“Influenza can be especially severe for the most vulnerable populations, including the elderly, young children and those with compromised immune systems,” according to Greenberg. It can also have a serious health impact on otherwise healthy individuals.
“Last season, our influenza vaccine represented nearly 50 percent of the U.S. influenza vaccine supply, and we anticipate our global supply of Fluzone High-Dose vaccine will increase significantly over the next few years,” Vice President Vaccines Industrial Affairs U.S. and Site Head Franck Chassant said.
Flu vaccine sales are going so well, that Sanofi intends to build an entire new building to support their flu vaccine venture.